These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 17290721)
1. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Garza CA; Montori VM; McConnell JP; Somers VK; Kullo IJ; Lopez-Jimenez F Mayo Clin Proc; 2007 Feb; 82(2):159-65. PubMed ID: 17290721 [TBL] [Abstract][Full Text] [Related]
2. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Persson M; Hedblad B; Nelson JJ; Berglund G Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China. Wang C; Fang X; Hua Y; Liu Y; Zhang Z; Gu X; Wu X; Tang Z; Guan S; Liu H; Liu B; Guo X; Ji X Angiology; 2018 Jan; 69(1):49-58. PubMed ID: 28429599 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis. Garg PK; McClelland RL; Jenny NS; Criqui MH; Greenland P; Rosenson RS; Siscovick DS; Jorgensen N; Cushman M Atherosclerosis; 2015 Jul; 241(1):176-82. PubMed ID: 26004387 [TBL] [Abstract][Full Text] [Related]
5. The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. Allison MA; Denenberg JO; Nelson JJ; Natarajan L; Criqui MH J Vasc Surg; 2007 Sep; 46(3):500-6. PubMed ID: 17681710 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome. Xu C; Yu F; Mao S; Shi Y; Li Q; Fang S; Tan Y; Gu W; Ye L Respir Med; 2020 Mar; 163():105881. PubMed ID: 32056835 [TBL] [Abstract][Full Text] [Related]
8. The relationships between biological novel biomarkers Lp-PLA Chen Y; Wang S; Li J; Fu Y; Chen P; Liu X; Zhang J; Sun L; Zhang R; Li X; Liu L J Diabetes; 2024 Jul; 16(7):e13574. PubMed ID: 38924255 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. Theocharidou E; Tellis CC; Mavroudi M; Soufleris K; Gossios TD; Giouleme O; Athyros VG; Tselepis AD; Karagiannis A J Crohns Colitis; 2014 Sep; 8(9):936-44. PubMed ID: 24529818 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Tsimikas S; Willeit J; Knoflach M; Mayr M; Egger G; Notdurfter M; Witztum JL; Wiedermann CJ; Xu Q; Kiechl S Eur Heart J; 2009 Jan; 30(1):107-15. PubMed ID: 19019993 [TBL] [Abstract][Full Text] [Related]
11. Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study. Garg PK; Arnold AM; Hinckley Stukovsky KD; Koro C; Jenny NS; Mukamal KJ; Criqui MH; Furberg CD; Newman AB; Cushman M Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):750-6. PubMed ID: 26848158 [TBL] [Abstract][Full Text] [Related]
12. Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection. Ross Eckard A; Longenecker CT; Jiang Y; Debanne SM; Labbato D; Storer N; McComsey GA HIV Med; 2014 Oct; 15(9):537-46. PubMed ID: 24650269 [TBL] [Abstract][Full Text] [Related]
13. [Lipoprotein-associated phospholipase A2 serum levels in patients from different categories of cardiovascular risk]. Nozadze DN; Sergienko IV; Balakhonova TV; Semenova AE; Vlasik TN; Kukharchuk VV Kardiologiia; 2014; 54(3):57-63. PubMed ID: 25102750 [TBL] [Abstract][Full Text] [Related]
14. Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia. Güngör ZB; Tüten A; Ekmekçi H; Ekmekçi ÖB; Kucur M; Öncül M; Donma O; Madazlı R; Sönmez H J Matern Fetal Neonatal Med; 2018 Dec; 31(23):3119-3127. PubMed ID: 28784006 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Madjid M; Ali M; Willerson JT Tex Heart Inst J; 2010; 37(1):25-39. PubMed ID: 20200624 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Sudhir K Vasc Health Risk Manag; 2006; 2(2):153-6. PubMed ID: 17319459 [TBL] [Abstract][Full Text] [Related]
17. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022 [TBL] [Abstract][Full Text] [Related]